Prospect: information for the patient
Jinarc 15 mg tablets
Jinarc 30 mg tablets
Jinarc 45 mg tablets
Jinarc 60 mg tablets
Jinarc 90 mg tablets
Tolvaptan
This medicine is subject to additional monitoring, which will speed up the detection of new information about its safety. You can contribute by reporting any adverse effects you may experience. The final part of section 4 includes information on how to report these adverse effects.
Read this prospect carefully before starting to take this medicine, because
it contains important information for you.
Jinarc is a medication used to treat a disease known as «autosomal dominant polycystic kidney disease» (ADPKD). This disease leads to the development of fluid-filled cysts in the kidneys, causing pressure on surrounding tissues and reducing kidney function, potentially leading to kidney failure. Jinarc is used to treat ADPKD in adults with chronic kidney disease (CKD) in stages 1 to 4 with signs of rapid disease progression.
The active ingredient of Jinarc is tolvaptan, which blocks the effect of vasopressin, a hormone involved in the formation of cysts in the kidneys of patients with ADPKD. By blocking the effect of vasopressin, Jinarc slows the development of kidney cysts in patients with ADPKD, reduces disease symptoms, and increases urine production.
Do not take Jinarc:
Warnings and precautions
Consult your doctor before starting to take Jinarc:
During treatment with Jinarc, your doctor will request monthly blood tests to monitor changes in your liver function.
Drink a sufficient amount of water
Jinarc causes water loss because it increases urine production. This water loss may lead to adverse effects such as dry mouth and thirst, or even more serious adverse effects such as kidney problems (see section 4). Therefore, it is essential that you have access to water and can ingest sufficient amounts of liquid when you feel thirsty. Before going to bed, you should drink one or two glasses of water even if you do not feel thirsty, and also drink water after urinating at night. You should be especially careful if you have a disease that reduces your ability to ingest adequate liquids or if you have a higher risk of dehydration, for example, if you have vomiting or diarrhea. Due to the increased urine production, it is also essential to have a bathroom nearby at all times.
Children and adolescents
Jinarc has not been studied in children and adolescents (under 18 years) and is therefore not recommended for use in this population.
Other medications and Jinarc
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, including over-the-counter medications.
Particularly, inform your doctor that you are taking:
It may not be a problem to take these medications at the same time as Jinarc. Your doctor will decide what is best for you.
Use of Jinarc with beverages and alcohol
Do not take orange juice while taking Jinarc.
Pregnancy and breastfeeding
Do nottake this medication if you are pregnant or breastfeeding.
Potentially fertile women should use reliable contraceptive methods while being treated with this medication.
If you are pregnant or breastfeeding, or if you think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before taking this medication.
Driving and operating machinery
Some people may feel dizzy, weak, or tired after taking Jinarc. If you experience these effects, do not drive or use tools or machines.
Jinarc contains lactose.
If your doctor has told you that you have a lactose intolerance, consult with them before taking this medication.
Only specialized doctors in the treatment of PQRAD can prescribe Jinarc. Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Dose
The daily dose of Jinarc should be divided into two doses, one higher than the other. The higher dose should be taken in the morning when waking up, at least 30 minutes before breakfast, while the lower dose should be taken 8 hours later.
The dose combinations are:
45 mg + 15 mg
60 mg + 30 mg
90 mg + 30 mg
Normally, your treatment will start with a dose of 45 mg in the morning and 15 mg 8 hours later. Your doctor may gradually increase your dose to a maximum combination of 90 mg in the morning and 30 mg 8 hours later. Your doctor will regularly check how you tolerate the prescribed dose to determine the best dose for you. Always take the highest tolerable dose combination prescribed by your doctor.
If you are taking other medications that may increase the effects of Jinarc, you may receive lower doses. In this case, your doctor may prescribe Jinarc tablets with 30 or 15 mg of tolvaptan, which you should take once a day in the morning.
Administration form
Swallow the tablets without chewing and with a glass of water.
The morning dose should be taken at least 30 minutes before breakfast. The second daily dose can be taken with or without food.
If you take more Jinarc than you should
In case you have taken more tablets than the prescribed dose,drink plenty of water and immediately contact your doctor or the nearest hospital.Remember to bring the medication package with you so it is clear what you have taken. If you take the higher dose too late, you may have to go to the bathroom more frequently at night.
If you forget to take Jinarc
If you forget to take your medication, take the dose as soon as you remember on the same day. If you have not taken the tablets for a day, take the normal dose the next day.Do not take a double dose to compensate for the missed individual doses.
If you interrupt the treatment with Jinarc
If you interrupt the treatment with Jinarc, the kidney cysts may grow as fast as before starting the treatment with this medication. Therefore, you should only stop taking Jinarc if you notice emergency medical attention required side effects (see section 4) or if your doctor tells you to.
If you have any doubts about the use of this medication, consult your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
Severe side effects:
If you experience any of the following side effects, you may need urgent medical attention. Stop taking Jinarc and contact a doctor immediately or go to the nearest hospital if:
Jinarc may cause your liver not to function properly.
Consult your doctor if you experience symptoms of nausea, vomiting, fever, fatigue, loss of appetite, abdominal pain, dark urine, jaundice (yellowing of the skin or eyes), skin itching, or joint and muscle pain with fever.
Other side effects:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Rare: may affect up to 1 in 100 people
Unknown frequency: cannot be estimated from available data
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national notification system included in theAppendix V.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the outer box, on the blister pack, and on the blister after the abbreviation «CAD». The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from light and moisture.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. This will help protect the environment.
Composition of Jinarc
The active ingredient is tolvaptan.
Each Jinarc 15 mg tablet contains 15 mg of tolvaptan.
Each Jinarc 30 mg tablet contains 30 mg of tolvaptan.
Each Jinarc 45 mg tablet contains 45 mg of tolvaptan.
Each Jinarc 60 mg tablet contains 60 mg of tolvaptan.
Each Jinarc 90 mg tablet contains 90 mg of tolvaptan.
The other components are lactose monohydrate (see section 2), maize starch, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate and aluminium lake of indigo carmine.
Appearance of Jinarc and contents of the pack
The different doses of Jinarc tablets have different shapes and markings:
Jinarc 15 mg tablet: blue, triangular, marked with "OTSUKA" and "15" on one side.
Jinarc 30 mg tablet: blue, round, marked with "OTSUKA" and "30" on one side.
Jinarc 45 mg tablet: blue, square, marked with "OTSUKA" and "45" on one side.
Jinarc 60 mg tablet: blue, modified rectangular, marked with "OTSUKA" and "60" on one side.
Jinarc 90 mg tablet: blue, pentagonal, marked with "OTSUKA" and "90" on one side.
The medicinal product is supplied in the following pack sizes:
Jinarc 15 mg tablets: blisters with 7 or 28 tablets
Jinarc 30 mg tablets: blisters with 7 or 28 tablets
Jinarc 45 mg tablets + Jinarc 15 mg tablets: blisters with or without a carton with
14 (7 high-dose tablets + 7 low-dose tablets),
28 (14 high-dose tablets + 14 low-dose tablets) or
56 (28 high-dose tablets + 28 low-dose tablets) tablets.
Jinarc 60 mg tablets + Jinarc 30 mg tablets: blisters with or without a carton with 14 (7 high-dose tablets + 7 low-dose tablets),
28 (14 high-dose tablets + 14 low-dose tablets) or
56 (28 high-dose tablets + 28 low-dose tablets) tablets.
Jinarc 90 mg tablets + Jinarc 30 mg tablets: blisters with or without a carton with
14 (7 high-dose tablets + 7 low-dose tablets),
28 (14 high-dose tablets + 14 low-dose tablets) or
56 (28 high-dose tablets + 28 low-dose tablets) tablets.
Only some pack sizes may be marketed.
Marketing authorisation holder
Otsuka Pharmaceutical Netherlands B.V.
Herikerbergweg 292
1101 CT, Amsterdam
Netherlands
Manufacturer
AndersonBrecon (UK) Limited
Units 2-7, Wye Valley Business Park, Brecon Road, Hay-on-Wye
Hereford - HR3 5PG
UK
Almac Pharma Services Ltd.
Almac House, 20 Seagoe Industrial Estate
Craigavon - BT63 5QD
UK
Almac Pharma Service (Ireland) Limited
Finnabair Industrial Estate, Dundalk,
Co. Louth - A91 P9KD
Ireland
Millmount Healthcare Limited
Block-7, City North Business Campus, Stamullen, Co.
Meath, K32 YD60
Ireland
For further information about this medicinal product, please contact the local representative of the marketing authorisation holder:
België/Belgique/Belgien Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 | Lietuva Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 |
???????? Otsuka Pharmaceutical Netherlands B.V. Te?: +31 (0) 20 85 46 555 | Luxembourg/Luxemburg Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 |
Ceská republika Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 | Magyarország Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 |
Danmark Otsuka Pharma Scandinavia AB Tlf: +46854 528 660 | Malta Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 |
Deutschland Otsuka Pharma GmbH Tel: +49691 700 860 | Nederland Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 |
Eesti Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 | Norge Otsuka Pharma Scandinavia AB Tlf: +46854 528 660 |
Ελλ?δα Otsuka Pharmaceutical Netherlands B.V. Thλ:+31 (0) 20 85 46 555 | Österreich Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 |
España Otsuka Pharmaceutical S.A Tel: +3493 2081 020 | Polska Otsuka Pharmaceutical Netherlands B.V. Tel:+31 (0) 20 85 46 555 |
France Otsuka Pharmaceutical France SAS Tél: +33147 080 000 | Portugal Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 |
Hrvatska Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 | România Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 |
Ireland Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 | Slovenija Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 |
Ísland Otsuka Pharma Scandinavia AB Sími: +46854 528660 | Slovenská republika Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 |
Italia Otsuka Pharmaceutical Italy S.r.l. Tel: +39 02 00 63 27 10 | Suomi/Finland Otsuka Pharma Scandinavia AB Puh/Tel: +46854 528 660 |
Κ?προς Otsuka Pharmaceutical Netherlands B.V. Thλ:+31 (0) 20 85 46 555 | Sverige Otsuka Pharma Scandinavia AB Tel: +46854 528 660 |
Latvija Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555 | United Kingdom Otsuka Pharmaceuticals (UK) Ltd. Tel: +44 (0)203 747 5300 |
Date of last revision of this leaflet: MM/AAAA.
Other sources of information
Further detailed information on this medicinal product is available on the website of the European Medicines Agency:
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.